Miles Capital’s Emergent Biosolutions EBS Stock Holding History

Miles Capital’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-6,072	Closed	-$221K	–	189
2016 Q1	$221K	Buy	+6,072	New	+$214K	0.15%	152
2015 Q1	–	Sell	-12,005	Closed	-$327K	–	159
2014 Q4	$327K	Sell	12,005 -556	-4%	-$13.3K	0.18%	102
2014 Q3	$268K	Hold	12,561	–	–	0.14%	102
2014 Q2	$282K	Buy	+12,561	New	+$293K	0.14%	105

Other funds holding EBS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Miles Capital's EBS Position: Q2 2016 in Review

Miles Capital sold out of Emergent Biosolutions (EBS) in Q2 2016, closing a stake of 6,072 shares — an estimated $221K sold.

Miles Capital first reported a position in EBS in Q2 2014 and held it in 4 quarters. The position peaked at $327K in Q4 2014. 225 funds tracked by Wall St. Rank hold EBS as of Q2 2016.

Miles Capital reported no remaining Emergent Biosolutions position as of Q2 2016 after selling out during the quarter.
Miles Capital sold 6,072 Emergent Biosolutions shares in Q2 2016, an estimated $221K.
Miles Capital first reported a position in Emergent Biosolutions in Q2 2014 and held it in 4 quarters.
Miles Capital's Emergent Biosolutions position peaked at $327K in Q4 2014.
225 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2016.

Based on Miles Capital's 13F filing for Q2 2016, filed 11 Aug 2016.